HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251

Benzinga Newsdesk www.benzinga.com Positive 67.0%

Neg 0% Neu 0% Pos 67%

HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.